Skip to content
RCKTRocket Pharmaceuticals, Inc.

Earnings

When Rocket Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.

51 quarters. Mar 31, 2014 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 25, after the close

Thu, Feb 25, 2027in 99 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 24 – Mar 10

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$0.00
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
Net income
-$42.54M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$0.00No Q3 2025 on file

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    $0.00
    —
    Net income
    -$49.23M
    N/M
    EPS
    -$0.43
    N/M
    Read · nothing to show
  2. Q2 2026Aug 10, 2026, after the closeThe release4.4%by the close of Aug 11
    Revenue
    $0.00
    —
    Net income
    $123.21M
    N/M
    EPS
    $1.08
    N/M
  3. Q1 2026May 7, 2026, after the closeThe release1.1%by the close of May 8
    Revenue
    $0.00
    —
    Net income
    -$47.59M
    N/M
    EPS
    -$0.42
    N/M
  4. Q4 2025Feb 26, 2026, after the closeThe release+10.6%by the close of Feb 27
    Revenue
    $0.00
    —
    Net income
    -$42.54M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 12, 202643 d10-Q$0.00—-$0.43—
Q2 2026Jun 30, 2026Aug 10, 2026 · after-hoursAug 10, 202641 d10-Q$0.00—$1.084.4%
Q1 2026Mar 31, 2026May 7, 2026 · after-hoursMay 7, 202637 d10-Q$0.00—-$0.421.1%
FY 2025
Q4 2025derivedDec 31, 2025Feb 26, 2026 · after-hoursFeb 26, 202657 d10-K$0.00——+10.6%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 6, 202537 d10-Q$0.00—-$0.45+0.6%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 7, 202538 d10-Q$0.00—-$0.627.7%
Q1 2025Mar 31, 2025May 8, 2025 · after-hoursMay 8, 202538 d10-Q$0.00—-$0.560.9%
FY 2024
Q4 2024derivedDec 31, 2024Feb 27, 2025 · after-hoursFeb 27, 202558 d10-K$0.00——+0.6%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$0.00—-$0.71+1.1%
Q2 2024Jun 30, 2024Aug 5, 2024 · after-hoursAug 6, 202437 d10-Q$0.00—-$0.748.4%
Q1 2024Mar 31, 2024May 6, 2024 · after-hoursMay 7, 202437 d10-Q$0.00—-$0.66—
Earlier years, FY 2014 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026458320
10-QAug 10, 2026342348
10-QMay 7, 2026211873
10-KFeb 26, 2026076551
10-QNov 6, 2025269474
10-QAug 7, 2025104996
10-QMay 8, 2025066898
10-KFeb 27, 2025029002
10-QNov 7, 2024123459
10-QAug 6, 2024091838

Provenance

ProvenanceData status and checks

Rocket Pharmaceuticals, Inc. · CIK 1281895 · Engraved from SEC EDGAR